# Iressa as Second Line Therapy in Advanced NSCLC-Asia

> **NCT00478049** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 163 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00478049
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-05
- **Final completion:** 2009-02
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2012-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00478049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00478049, "Iressa as Second Line Therapy in Advanced NSCLC-Asia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00478049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*